Lymphoma & Plasma Cell Disorders
From the Journals
In a subgroup analysis from ENDEAVOR, progression-free survival was more than doubled, compared with bortezomib.
The Bruton’s tyrosine kinase inhibitor was evaluated in a phase 2 trial.
LA JOLLA, CALIF. – Chidamide produced a higher response rate in relapsed/refractory PTCL patients than what was observed in a prior phase 2 trial...
SAN DIEGO – A CAR T-cell construct engineered to enhance T-cell persistence and immune function induced high complete remission rates in a phase 1...
Combined modality therapy (CMT) can improve survival in young patients with early stage Hodgkin lymphoma (HL), according to research published in...
A group of experts has proposed new consensus definitions and grading systems for cytokine release syndrome (CRS) and neurotoxicity related to...